HI
JNCE

Harbour Investments’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

Harbour Investments’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-78
Closed -$1K – 3914
2021
Q3 		$1K Buy
78
+4
+5% +$25 ﹤0.01% 3664
2021
Q2 		$1K Buy
74
+27
+57% +$224 ﹤0.01% 3706
2021
Q1 		$0 Buy
+47
New +$515 ﹤0.01% 3778

Other funds holding JNCE

DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Harbour Investments's JNCE Position: Q4 2021 in Review

Harbour Investments sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q4 2021, closing a stake of 78 shares — an estimated $1K sold.

Harbour Investments first reported a position in JNCE in Q1 2021 and held it in 3 quarters. The position peaked at $1K in Q3 2021. 124 funds tracked by Wall St. Rank hold JNCE as of Q4 2021.

  • Harbour Investments reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q4 2021 after selling out during the quarter.
  • Harbour Investments sold 78 Jounce Therapeutics, Inc. Common Stock shares in Q4 2021, an estimated $1K.
  • Harbour Investments first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2021 and held it in 3 quarters.
  • Harbour Investments's Jounce Therapeutics, Inc. Common Stock position peaked at $1K in Q3 2021.
  • 124 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q4 2021.

Based on Harbour Investments's 13F filing for Q4 2021, filed 16 Feb 2022.